Published Online
on December 6, 2004

A more recent version of this article appeared on December 21, 2004

This Article Full Text (PDF) All Versions of this Article: 110/25/3822    most recent 01.CIR.0000150400.15354.7Dv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khanna, A. K. Articles by Ledbetter, S. Search for Related Content PubMed PubMed Citation Articles by Khanna, A. K. Articles by Ledbetter, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOSPORIN A Medline Plus Health Information Heart Transplantation Kidney Diseases Related Collections Animal models of human disease Gene expression Transplantation

Submitted on June 9, 2004
Revised on July 29, 2004
Accepted on August 11, 2004

Anti-Transforming Growth Factor Antibody at Low but Not High Doses Limits Cyclosporine-Mediated Nephrotoxicity Without Altering Rat Cardiac Allograft Survival. Potential of Therapeutic Applications

Ashwani K. Khanna PhD^*, Matthew S. Plummer BS, Gail Hilton BS, Galen M. Pieper PhD, and Steven Ledbetter PhD

From the Division of Nephrology (A.K.K., M.S.P.), and Division of Transplant Surgery (G.H., G.M.P.), Medical College of Wisconsin, Milwaukee, and Genzyme Corporation, Boston, Mass (S.L.).

^* To whom correspondence should be addressed. E-mail: akkhanna{at}mcw.edu.

Background--Long-term treatment of cardiac transplant recipients with cyclosporine results in a progressive decline in kidney function in a large number of patients. This complication is one of the most important prognostic parameters that determine the outcome of cardiac transplantation. Transforming growth factor- (TGF-) is one of the most potent mediators of the fibrogenic effects of cyclosporine.

Methods and Results--With the use of an experimental rodent model, heterotopic heart transplantation was performed, creating histocompatibility-disparate allografts. Because TGF- in part mediates both the immunosuppressive and nephrotoxic effects of cyclosporine, recipients were treated with cyclosporine with and without anti-TGF- antibody to determine whether anti-TGF- antibody could reduce the nephrotoxic effects of cyclosporine. Intrarenal expression of TGF-, collagen, fibronectin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-2 was studied with the use of reverse transcription-polymerase chain reaction. Intrarenal expression of TGF- protein was studied by immunohistochemistry and with the use of ELISA to quantify circulating levels of TGF- protein in plasma. Cyclosporine-induced graft survival (immunosuppressive effect) was abrogated with a higher concentration (2.5 mg/kg) of anti-TGF- antibody, whereas a lower concentration (1 mg/kg) inhibited both cyclosporine-induced expression of fibrogenic molecules and renal toxicity.

Conclusions--These results provide credence to the pivotal role of TGF- in immunosuppression-associated renal toxicity in recipients of cardiac transplantation. Furthermore, these findings support a potentially significant therapeutic use of optimal concentration of anti-TGF- antibody to ameliorate cyclosporine-associated nephrotoxicity in cardiac transplant recipients.

Key words: transplantation • coronary disease • kidney • transforming growth factors

This article has been cited by other articles:

				A. K. Khanna, J. Xu, P. A. Uber, A. P. Burke, C. Baquet, and M. R. Mehra Tobacco Smoke Exposure in Either the Donor or Recipient Before Transplantation Accelerates Cardiac Allograft Rejection, Vascular Inflammation, and Graft Loss Circulation, November 3, 2009; 120(18): 1814 - 1821. [Abstract] [Full Text] [PDF]

				K. A. Harradine, K. Ridd, E. F. Saunier, F. F. Clermont, J. Perez-Losada, D. H. Moore, E. H. Epstein Jr., B. C. Bastian, and R. J. Akhurst Elevated Cutaneous Smad Activation Associates with Enhanced Skin Tumor Susceptibility in Organ Transplant Recipients Clin. Cancer Res., August 15, 2009; 15(16): 5101 - 5107. [Abstract] [Full Text] [PDF]

				G. M. Pieper, I. A. Ionova, B. C. Cooley, R. Q. Migrino, A. K. Khanna, J. Whitsett, and J. Vasquez-Vivar Sepiapterin Decreases Acute Rejection and Apoptosis in Cardiac Transplants Independently of Changes in Nitric Oxide and Inducible Nitric-Oxide Synthase Dimerization J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 890 - 899. [Abstract] [Full Text] [PDF]

				A. K. Khanna and G. M. Pieper Reply Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2403 - 2403. [Full Text] [PDF]